<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33216044</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1877-718X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Journal of Parkinson's disease</Title><ISOAbbreviation>J Parkinsons Dis</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal Fluid Profiles in Parkinson's Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment.</ArticleTitle><Pagination><StartPage>221</StartPage><EndPage>232</EndPage><MedlinePgn>221-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JPD-202310</ELocationID><Abstract><AbstractText Label="BACKGROUND">As mutations in glucocerebrosidase 1 (GBA1) are a major risk factor for Parkinson's disease (PD), decreased GBA1 activity might play an important role in the pathogenesis of the disease. However, there are currently no reports on glucosylceramide levels in the cerebrospinal fluid (CSF) in PD.</AbstractText><AbstractText Label="OBJECTIVE">We investigated whether glucosylceramide accumulation and abnormal immune status in the brain are associated with PD.</AbstractText><AbstractText Label="METHODS">We measured glucosylceramide by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) as well as levels of the active fragment of complement C5, C5a, in the CSF of 33 PD, 15 amyotrophic lateral sclerosis (ALS) and 22 neurologically normal control (NNC) subjects. Serum C5a levels in all PD and ALS cases and in a limited number of NNC subjects (n&#x200a;=&#x200a;8) were also measured.</AbstractText><AbstractText Label="RESULTS">C5a levels in CSF were significantly downregulated in PD compared with NNC. Moreover, CSF C5a/serum C5a ratio showed pronounced perturbations in PD and ALS patients. LC-ESI-MS/MS revealed a statistically significant accumulation of a specific subspecies of glucosylceramide (d18&#x200a;:&#x200a;1/C23&#x200a;:&#x200a;0 acyl chain fatty acid) in ALS, but not in PD. Interestingly, CSF glucosylceramide (d18&#x200a;:&#x200a;1/C23&#x200a;:&#x200a;0) exhibited a significant correlation with CSF C5a levels in PD, but not ALS. No correlation was observed between C5a levels or glucosylceramide subspecies content and disease duration, levodopa equivalent daily dose or Hoehn &amp; Yahr staging in PD.</AbstractText><AbstractText Label="CONCLUSION">Our findings demonstrate complement dysregulation without glucosylceramide accumulation in PD CSF. Furthermore, we found an association between a specific glucosylceramide subspecies and immune status in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niimi</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizutani</LastName><ForeName>Yasuaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Hisako</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>RIKEN Center for Brain Science, Wako, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Hirohisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiroki</LastName><ForeName>Ryoichi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirabayashi</LastName><ForeName>Yoshio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>RIKEN Cluster for Pioneering Research, RIKEN, Wako, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoshinaga</LastName><ForeName>Kiyotaka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Urology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutoh</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Parkinsons Dis</MedlineTA><NlmUniqueID>101567362</NlmUniqueID><ISSNLinking>1877-7171</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003182">Complement C5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005963">Glucosylceramides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003182" MajorTopicYN="N">Complement C5</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005963" MajorTopicYN="N">Glucosylceramides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021241" MajorTopicYN="N">Spectrometry, Mass, Electrospray Ionization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">glycosphingolipids</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">mass spectrometry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33216044</ArticleId><ArticleId IdType="doi">10.3233/JPD-202310</ArticleId><ArticleId IdType="pii">JPD202310</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>